Dasatinib Tablet Manufacturer, Exporter & Global Supplier

Dasatinib Tablet Manufacturer, as a WHO-GMP certified we specialize in delivering high-quality oncology medicines to global markets at affordable prices. Dasatinib Tablets are a targeted therapy widely prescribed in the treatment of specific types of blood cancers such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Classified as a tyrosine kinase inhibitor (TKI), Dasatinib works by blocking abnormal proteins that cause cancer cells to multiply uncontrollably. This makes it one of the most effective modern oral therapies for managing certain hematologic malignancies.

About Dasatinib Tablets

Dasatinib acts on multiple tyrosine kinases including BCR-ABL, SRC family kinases, and others that are central to the growth of leukemia cells. By inhibiting these proteins, the drug slows down or stops cancer progression, giving patients a better chance at remission. Our expertise as a reputed Dasatinib Tablet Manufacturer ensures that each formulation meets stringent quality standards to support oncology treatment protocols worldwide.

Key Uses and Benefits

• Chronic Myeloid Leukemia (CML): Effective in newly diagnosed as well as resistant/intolerant cases.

• Acute Lymphoblastic Leukemia (ALL): Used in Philadelphia chromosome-positive ALL patients.

• Broad Tyrosine Kinase Inhibition: Helps manage cases resistant to other TKIs.

• Oral Administration: Convenient once-daily oral dosing improves patient compliance.

• Trusted Oncology Therapy: As a leading Dasatinib Tablet Manufacturer, we supply to hospitals, oncology centers, and global healthcare organizations.

Dosage and Administration

Dasatinib Tablets are usually prescribed once daily, with or without food, based on the specific cancer type and stage of treatment. Dosage may vary between 50 mg to 140 mg depending on the medical condition and physician’s judgment. As an experienced Dasatinib Tablet Manufacturer, we offer multiple strengths and customized packaging to meet both regulated and semi-regulated market requirements.

Precautions

As a responsible Dasatinib Tablet Manufacturer, we highlight the following precautions:

• Not recommended for patients with significant liver or lung impairment without strict monitoring.

• Risk of bleeding, fluid retention, and pulmonary arterial hypertension requires regular medical evaluation.

• Drug interactions may occur with strong CYP3A4 inhibitors/inducers; consultation with a physician is essential.

• Pregnant and breastfeeding women should avoid Dasatinib due to potential risks to the fetus or infant.

• Patients should not crush or chew the tablets; they must be swallowed whole with water.

Possible Side Effects

While highly effective, Dasatinib may cause some side effects such as:

• Nausea, vomiting, or diarrhea

• Fatigue and weakness

• Headache or skin rash

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Fluid retention including pleural effusion

• Rare but serious pulmonary hypertension

With our expertise as a globally trusted Dasatinib Tablet Manufacturer, we ensure proper labeling, safety instructions, and pharmacovigilance support to minimize risks.

Why Choose Us?

• WHO-GMP and ISO-certified Dasatinib Tablet Manufacturer in India.

• Recognized as a reliable exporter and global supplier to oncology markets worldwide.

• Wide distribution network across Asia, Africa, Middle East, and Latin America.

• Flexible contract manufacturing and third-party production services.

• Affordable oncology solutions without compromising international quality standards.

Our commitment to excellence, global accessibility, and patient safety has positioned us as a dependable Dasatinib Tablet Manufacturer. By providing high-quality oncology therapies, we aim to support healthcare providers and patients worldwide in the fight against blood cancers.

Global Distribution Network

With a strong logistics and compliance framework, we successfully export Dasatinib Tablet  to a broad range of international markets, including: Venezuela, Brazil, Cambodia, Philippines, Nigeria, Myanmar, Thailand, Singapore, Russia, Kyrgyzstan, Tajikistan, Kenya, Zimbabwe, Somalia, Djibouti, Belarus, Macedonian, And Turkey.